Achilles Therapeutics Discontinues cNeT Program and Closes Early-to-Mid Stage Studies For Cancer Treatment

MT Newswires Live09-19

Achilles Therapeutics (ACHL) said Thursday that it is discontinuing its TIL-based cNeT program and closing the phase I/II clinical trials for non-small cell lung cancer treatment.

The company said it would change its strategy to pursue partnerships with third parties developing alternative treatments for clonal neoantigens, such as neoantigen vaccines, ADCs, and TCR-T therapies.

Achilles has also hired BofA Securities to investigate value-maximizing strategies.

As of June 30, 2024, the company had $95.1 million in cash.

The company said it would also reduce its workforce and implement cost-cutting measures while retaining key employees for the strategic review.

Shares of the company were up nearly 47% in recent Thursday premarket activity.

Price: 1.0200, Change: +0.33, Percent Change: +47.29

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468758185?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-19 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468758185","market":"hk","top_or_hot":-1,"title":"Achilles Therapeutics Discontinues cNeT Program and Closes Early-to-Mid Stage Studies For Cancer Treatment","media":"MT Newswires Live","content":"<html><body><p> Achilles <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ACHL) said Thursday that it is discontinuing its TIL-based cNeT program and closing the phase I/II clinical trials for non-small cell lung cancer treatment.</p><p>The company said it would change its strategy to pursue partnerships with third parties developing alternative treatments for clonal neoantigens, such as neoantigen vaccines, ADCs, and TCR-T therapies.</p><p>Achilles has also hired BofA Securities to investigate value-maximizing strategies.</p><p>As of June 30, 2024, the company had $95.1 million in cash.</p><p>The company said it would also reduce its workforce and implement cost-cutting measures while retaining key employees for the strategic review.</p><p>Shares of the company were up nearly 47% in recent Thursday premarket activity.</p><p>Price: 1.0200, Change: +0.33, Percent Change: +47.29</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Achilles Therapeutics Discontinues cNeT Program and Closes Early-to-Mid Stage Studies For Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAchilles Therapeutics Discontinues cNeT Program and Closes Early-to-Mid Stage Studies For Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-19 20:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Achilles Therapeutics (ACHL) said Thursday that it is discontinuing its TIL-based cNeT program and closing the phase I/II clinical trials for non-small cell lung cancer treatment.The company said it ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SSI","symbol_name":"Stage Stores Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2468758185","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468758185","pubTimestamp":1726747486,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Achilles Therapeutics  said Thursday that it is discontinuing its TIL-based cNeT program and closing the phase I/II clinical trials for non-small cell lung cancer treatment.The company said it would change its strategy to pursue partnerships with third parties developing alternative treatments for clonal neoantigens, such as neoantigen vaccines, ADCs, and TCR-T therapies.Achilles has also hired BofA Securities to investigate value-maximizing strategies.As of June 30, 2024, the company had $95.1 million in cash.The company said it would also reduce its workforce and implement cost-cutting measures while retaining key employees for the strategic review.Shares of the company were up nearly 47% in recent Thursday premarket activity.Price: 1.0200, Change: +0.33, Percent Change: +47.29","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SSI":"Stage Stores Inc","LENZ":"Therapeutics","BK4139":"生物科技","BK4539":"次新股","ACHL":"Achilles Therapeutics plc"},"translate_title":"Achilles Therapeutics终止cNeT项目并关闭癌症治疗的早期至中期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACHL":1,"LENZ":1,"SSI":1},"content_text":"Achilles Therapeutics (ACHL) said Thursday that it is discontinuing its TIL-based cNeT program and closing the phase I/II clinical trials for non-small cell lung cancer treatment.The company said it would change its strategy to pursue partnerships with third parties developing alternative treatments for clonal neoantigens, such as neoantigen vaccines, ADCs, and TCR-T therapies.Achilles has also hired BofA Securities to investigate value-maximizing strategies.As of June 30, 2024, the company had $95.1 million in cash.The company said it would also reduce its workforce and implement cost-cutting measures while retaining key employees for the strategic review.Shares of the company were up nearly 47% in recent Thursday premarket activity.Price: 1.0200, Change: +0.33, Percent Change: +47.29","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468758185"}